- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03080077
Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia (CXL)
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
- 10 years of age or older
- Understand and have signed written IRB-approved informed consent
- Willingness and ability to comply with schedule for follow-up visits
- Having a diagnosis of keratoconus or post-refractive corneal ectasia (post-LASIK or PRK)
- Presence of central or inferior steepening on the Pentacam map
- Axial topography consistent with keratoconus or post-refractive corneal ectasia (post-LASIK or PRK)
Presence of one or more slit lamp findings associated with keratoconus, such as:
- Scissoring of the retinoscopic reflex
- Fleischer ring
- Vogt striae
- Corneal thinning
- Corneal scarring
- BSCVA 20/20 or worse (<58 letters on ETDRS chart).
- Contact lens wearers only: Removal of contact lenses for the required period of time prior to the first refraction:
Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks Hybrid lenses (SynergEyes; Rose K; Clear Kone) 2 Weeks Scleral Lenses 2 Weeks
Exclusion Criteria: All subjects meeting any of the following criteria will be excluded from the study:
A history of previous corneal surgery in the eye to be treated (including previous CXL treatment)
a. Eyes with episodes of hydrops or scarring from hydrops may be included as long as there is no active inflammation
- Corneal pachymetry < 400 microns at the thinnest point measured by Pentacam
Previous ocular condition (other than refractive error) in the eye(s) to be treated that may predispose the eye for future complications or prevent the possibility of improved vision, for example:
- History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, or corneal dystrophy, etc.)
- Clinically significant corneal scarring in the treatment zone
- A history of chemical injury or delayed epithelial healing in the eye(s) to be treated
- Pregnancy (including plan to become pregnant) or lactation during the procedure
- A known sensitivity to study medications
- Nystagmus or any other condition that would prevent a steady gaze during the cross-linking treatment or other diagnostic tests
- A condition that, in the investigator's opinion, would interfere with or prolong epithelial healing
- Presence or history of any other condition or finding that, in the investigator's opinion, makes the patient unsuitable as a candidate for cross-linking or study participation or may confound the outcome of the study
- Inability to cooperate with diagnostic tests or inability to understand the informed consent.
- Concurrent use of systemic (including inhaled) medications that may impair healing, including but not limited to: antimetabolites, isotretinoin (Accutane®) within 6 months of treatment, and amiodarone hydrochloride (Cordarone®) within 12 months of treatment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Epi-Off CXL
Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea.
The epithelium will be removed by gently brushing the cornea with a scalpel.
A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry.
Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization.
Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
|
Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea.
The epithelium will be removed by gently brushing the cornea with a scalpel.
A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry.
Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization.
Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
|
EXPERIMENTAL: Epi-On CXL
The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated.
The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle.
The generator will be switched on and set to 1 mA for 5 minutes.
The generator will then be disconnected and the applicator will be removed from the cornea.
|
The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated.
The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle.
The generator will be switched on and set to 1 mA for 5 minutes.
The generator will then be disconnected and the applicator will be removed from the cornea.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Kmax
Time Frame: baseline and 2 years
|
Kmax = maximum simulated keratometry value
|
baseline and 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in steepest K
Time Frame: baseline and 2 years
|
steepest K is the higher diopter number which represents the steepest meridian of the cornea
|
baseline and 2 years
|
Change in astigmatism
Time Frame: baseline and 2 years
|
Astigmatism is an imperfection in the curvature of the cornea, causing a refractive error diagnosed by standard eye exam with refraction test.
|
baseline and 2 years
|
Change in keratometry
Time Frame: baseline and 2 years
|
Keratometry is the measurement of the corneal radius of curvature
|
baseline and 2 years
|
Change in pachymetry
Time Frame: baseline and 2 years
|
Pachymetry is a common test for glaucoma and measures the thickness of the cornea
|
baseline and 2 years
|
Changes in curvature
Time Frame: baseline and 2 years
|
Shape of cornea
|
baseline and 2 years
|
Change in sphere
Time Frame: baseline and 2 years
|
Change in refraction
|
baseline and 2 years
|
Change in cylinder
Time Frame: 2 years
|
Cylinder is the amount of astigmatism that is present
|
2 years
|
Change in BCVA
Time Frame: baseline and 2 years
|
Best-corrected visual acuity (BCVA)
|
baseline and 2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Penny A Asbell, MD, Icahn School of Medicine at Mount Sinai
Publications and helpful links
General Publications
- Lombardo M, Serrao S, Rosati M, Ducoli P, Lombardo G. Biomechanical changes in the human cornea after transepithelial corneal crosslinking using iontophoresis. J Cataract Refract Surg. 2014 Oct;40(10):1706-15. doi: 10.1016/j.jcrs.2014.04.024.
- Koller T, Schumacher S, Fankhauser F 2nd, Seiler T. Riboflavin/ultraviolet a crosslinking of the paracentral cornea. Cornea. 2013 Feb;32(2):165-8. doi: 10.1097/ICO.0b013e318269059b.
Study record dates
Study Major Dates
Study Start
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GCO 16-0627
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Keratoconus
-
The Cleveland ClinicUniversity of MarylandEnrolling by invitationKeratoconus | Keratoconus, Unstable | Keratoconus, StableUnited States
-
Eye Hospital Pristina KosovoActive, not recruitingKeratoconus | Keratoconus of Right Eye | Keratoconus, Unstable, Right EyeKosovo
-
Tianjin Eye HospitalRecruitingScansys, Pentacam, Keratoconus, Subclinical KeratoconusChina
-
Tianjin Eye HospitalActive, not recruitingScansys, Pentacam, Corvis ST, Keratoconus, Subclinical KeratoconusChina
-
Heba Allah Nashaat MohamedAssiut UniversityRecruitingKeratoconus, CollagenEgypt
-
Kent Wellish MDNot yet recruitingKeratoconus, Unstable
-
Kasr El Aini HospitalUnknownProgressive KeratoconusEgypt
-
Centre Hospitalier Régional Metz-ThionvilleCompletedProgressive Keratoconus
-
Glaukos CorporationCompletedProgressive KeratoconusUnited States
-
Tianjin Eye HospitalCompletedKeratoconus, StableChina
Clinical Trials on Epi-Off
-
Umeå UniversityGlaukos CorporationCompletedEye Diseases | Keratoconus | Corneal Disease | Corneal Crosslinking | Corneal Biomechanics | Corneal Densitometry | Scheimpflug PhotographySweden
-
Exosome Diagnostics, Inc.CompletedUrologic CancerUnited States, Germany
-
University of MoliseCompleted
-
University of California, Los AngelesUniversity of North Carolina, Chapel Hill; University of California, Irvine; Florida... and other collaboratorsRecruitingHIV InfectionsUnited States
-
Epigenomics, IncRecruitingColorectal Neoplasms | Colorectal CancerUnited States
-
Yale UniversityEdison Pharmaceuticals Inc; Rembrandt FoundationCompleted
-
Epigenomics, IncCompleted
-
ESSA PharmaceuticalsTerminatedGenital Neoplasms, Male | Prostatic Neoplasms | Prostatic Diseases | Genital Diseases, MaleUnited States, Canada
-
Walter Reed Army Medical CenterCompleted
-
Asociación para Evitar la Ceguera en MéxicoCompletedCorneal EpitheliumMexico